Cole, S. T.Alzari, P. M.2012-07-042012-07-042012-07-04200710.1042/BST0351321https://infoscience.epfl.ch/handle/20.500.14299/83472WOS:000251279800114The need for better drugs to treat tuberculosis has never been greater. Despite insufficient funding for discovery research, intensive efforts have been made to find and develop new lead compounds capable of reducing the duration of the present treatment known as DOTS (directly observed therapy short course), from 6 to under 4 months. This minireview describes the progress achieved during the last 5 years and highlights some of the successes without neglecting the problems.directly observed therapy short course (DOTS)moxifloxacinPa-824R207910serine/threonine kinaseSq109Multidrug-Resistant TuberculosisCombinatorial Lead OptimizationMycobacterium-TuberculosisIn-VitroNitroimidazopyran Pa-824Antituberculosis AgentsBactericidal ActivityMurine TuberculosisAtp SynthaseIdentificationTowards new tuberculosis drugstext::conference output::conference proceedings::conference paper